{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:43:53Z","timestamp":1791895433563,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clbc.2025.08.007","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T01:01:17Z","timestamp":1755651677000},"page":"e1141-e1149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real World Safety of Adjuvant Ultra Hypofractionated Radiotherapy in Nonmetastatic Breast Cancer: Acute Cutaneous Toxicity and Aesthetic Outcomes"],"prefix":"10.1016","volume":"25","author":[{"given":"Molka","family":"Mezghani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Ben Rejeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awatef","family":"Hamdoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihab","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Bouguerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Ghorbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotfi","family":"Kochbati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2025.08.007_bib0001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2025.08.007_bib0002","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jnci\/djh297","article-title":"Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial","volume":"97","author":"Ragaz","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2025.08.007_bib0003","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","article-title":"Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2025.08.007_bib0004","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(08)60348-7","article-title":"The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial","volume":"371","author":"Bentzen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2025.08.007_bib0005","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1470-2045(08)70077-9","article-title":"The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial","volume":"9","author":"Bentzen","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2025.08.007_bib0006","first-page":"272","article-title":"Are three weeks of whole-breast radiotherapy as good as five weeks in early breast cancer? 10-year follow-up in the Canadian trial of hypofractionated radiation therapy","volume":"5","author":"Whelan","year":"2010","journal-title":"Breast Care"},{"key":"10.1016\/j.clbc.2025.08.007_bib0007","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.20.01363","article-title":"Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ: the DBCG HYPO trial","volume":"38","author":"Offersen","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.08.007_bib0008","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S1470-2045(21)00539-8","article-title":"ESTRO ACROP consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer","volume":"23","author":"Meattini","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2025.08.007_bib0009","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year results from a phase 3 trial","volume":"395","author":"Murray Brunt","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2025.08.007_bib0024","article-title":"Acute toxicity of ultra-hypofractionated whole breast RT with boost","volume":"41","author":"Montero","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.clbc.2025.08.007_bib0012","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.21873\/anticanres.16660","article-title":"Simultaneous vs. sequential boost for adjuvant breast radiotherapy","volume":"43","author":"Eggert","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clbc.2025.08.007_bib0015","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3390\/medicina58060745","article-title":"Ultra-hypofractionated vs. moderate fractionated whole breast 3D conformal radiotherapy during COVID-19","volume":"58","author":"Ivanov","year":"2022","journal-title":"Medicina"},{"key":"10.1016\/j.clbc.2025.08.007_bib0022","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00066-022-01985-4","article-title":"Hypofractionated radiotherapy after breast-conserving surgery: predictive factors of skin toxicity","volume":"199","author":"Ben Amor","year":"2023","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.clbc.2025.08.007_bib0013","unstructured":"JING H. UNIQUE trial. clinicaltrials.gov; 2023 . NCT05762900. https:\/\/clinicaltrials.gov\/study\/NCT05762900."},{"key":"10.1016\/j.clbc.2025.08.007_bib0011","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1200\/JCO.19.02750","article-title":"Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy","volume":"38","author":"Brunt","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.08.007_bib0014","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/jco.jco_39_21","article-title":"FAST-forward trial in breast cancer: dosimetric and feasibility study in India","volume":"5","author":"Mohanapriya","year":"2022","journal-title":"J Curr Oncol"},{"key":"10.1016\/j.clbc.2025.08.007_bib0010","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2016.02.027","article-title":"Acute skin toxicity with 1-week vs 3-week whole breast radiotherapy in the UK FAST-Forward Trial","volume":"120","author":"Brunt","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clbc.2025.08.007_bib0016","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/0284186X.2020.1747638","article-title":"Two-year toxicity of hypofractionated radiotherapy in five fractions","volume":"59","author":"Van Hulle","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clbc.2025.08.007_bib0017","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijrobp.2011.05.065","article-title":"Risk factors of long-lasting breast pain after radiotherapy","volume":"83","author":"Lundstedt","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clbc.2025.08.007_bib0018","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1269\/jrr.10169","article-title":"Association between skin phototype and radiation dermatitis in breast cancer therapy","volume":"52","author":"Yamazaki","year":"2011","journal-title":"J Radiat Res"},{"key":"10.1016\/j.clbc.2025.08.007_bib0019","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.breast.2013.07.047","article-title":"Smoking as a risk factor for skin reactions in breast cancer radiotherapy","volume":"22","author":"Sharp","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2025.08.007_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.738851","article-title":"Risk factors for acute radiation dermatitis: systematic review and meta-analysis","volume":"11","author":"Xie","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2025.08.007_bib0021","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1186\/1471-2407-14-711","article-title":"Factors modifying risk of acute skin toxicity in whole-breast IMRT","volume":"14","author":"De Langhe","year":"2014","journal-title":"BMC Can"},{"key":"10.1016\/j.clbc.2025.08.007_bib0023","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.breast.2022.12.008","article-title":"Implementation of 26 Gy in five fractions over 1 week: acute skin toxicity report","volume":"67","author":"Nugent","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2025.08.007_bib0025","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.3390\/biomedicines10102568","article-title":"Ultra-hypofractionation in early breast cancer: interim analysis","volume":"10","author":"Sigaudi","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.clbc.2025.08.007_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.breast.2022.12.008","article-title":"Implementation of 26 Gy in five fractions over 1 week: acute skin toxicity report","volume":"67","author":"Nugent","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2025.08.007_bib27","article-title":"Acute toxicity of ultra-hypofractionated whole breast RT with boost","volume":"41","author":"Montero","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.clbc.2025.08.007_bib28","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.3390\/biomedicines10102568","article-title":"Ultra-hypofractionation in early breast cancer: interim analysis","volume":"10","author":"Sigaudi","year":"2022","journal-title":"Biomedicines"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925002344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925002344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:59:46Z","timestamp":1763751586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820925002344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1526820925002344"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.08.007","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real World Safety of Adjuvant Ultra Hypofractionated Radiotherapy in Nonmetastatic Breast Cancer: Acute Cutaneous Toxicity and Aesthetic Outcomes","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}